Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS

KROS Stock Forecast, Price Targets, Chart, Dividends & Analysis

Keros Therapeutics Inc. logo

Keros Therapeutics Inc.

Sector: Manufacturing   

Industry: Pharmaceutical Preparation Manufacturing

13.64
 
USD
  
-0.15
  
(-1.09%)
Previous close: 13.79  Open: 13.72  Bid: 13.5  Ask: 14.2
52 week range    
9.12   
   72.37
Mkt Cap: 558 M  Avg Vol (90 Days): 983,803
Last updated: Friday 13th June 2025

Stock Rankings

40
MarketXLS Rank
60
Value
18
Technical
42
Quality
How are these ranks calculated?
Metrics

Growth

Peers

StockDividendMarket Cap (B)PEPrice ($)
Financials

KROS Income Statement

Annual
Invalid dateDec-20Dec-21Dec-22Dec-23Dec-24
AccruedPreferredStockDividends45 M59 M105 M153 M187 M
Basic EPS from continuing operations-2.93-2.52-4.15-5.2-5.0
Basic EPS total-2.93-2.52-4.15-5.2-5.0
Basic weighted shares outstanding16 M23 M25 M29 M37 M
Depreciation300000.0400000.0700000.0815000.01 M
DepreciationAndAmortization300000.0400000.0700000.0815000.01 M
Diluted EPS total-2.93-2.52-4.15-5.2-5.0
Diluted normalized net income/share-2.52-4.15-5.2-5.0
Diluted weighted shares outstanding16 M23 M25 M29 M37 M
GeneralAndAdministrativeExpense13 M21 M28 M35 M41 M
Gross operating profit20 M151000.04 M
Income before tax-46 M-57 M-105 M-153 M-187 M
Income taxes-172000.02 M300000.0
Interest income-6000.0
InterestExpenseNonOperating6000.04000.01000.0
MiscOtherSpecialCharges3 M-356000.0-613000.0-206000.0-954000.0
Net income from total operations-45 M-59 M-105 M-153 M-187 M
NetIncomeCommonStockholders-45 M-59 M-105 M-153 M-187 M
NetIncomeContinuousOperations-45 M-59 M-105 M-153 M-187 M
NetNonOperatingInterestIncomeExpense-6000.0-4000.0-1000.0
Normalized income-209 M
Operating income-47 M-56 M-115 M-170 M-211 M
Operating income before depreciation (EBITDA)-45 M-56 M-103 M-151 M-184 M
OperatingExpense47 M76 M108 M170 M214 M
Other income net-1 M356000.03 M206000.0954000.0
Other special charges-4 M-15 M-23 M
OtherGandA13 M21 M28 M35 M41 M
OtherOperatingExpenses468000.0600000.02 M4 M-1 M
OtherunderPreferredStockDividend45 M59 M105 M153 M187 M
PreferredStockDividends45 M59 M105 M153 M187 M
Research & development expense34 M55 M87 M135 M174 M
ResearchExpense34 M55 M87 M135 M174 M
SalariesAndWages19 M29 M35 M
Selling Gen & administrative expense13 M21 M28 M35 M41 M
Special income/charges4 M15 M23 M
Total Income available for interest expense (EBIT)-46 M-57 M-105 M-153 M-187 M
Total common shares outstanding23 M29 M36 M41 M
Total net income-45 M-59 M-105 M-153 M-187 M
Total ordinary shares41 M41 M41 M41 M41 M
Total revenues20 M151000.04 M
TotalExpenses47 M76 M108 M170 M214 M
TotalRevenue20 M151000.04 M
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.

John D.

Financial Analyst

I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...

Kirubakaran K.

Investment Professional

MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.

David L.

Financial Analyst

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.

Lloyd L.

Professional Trader